Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics


Oncolytics Biotech Inc. (ONCY): $1.12

0.04 (+3.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ONCY Stock Price Chart Interactive Chart >

Price chart for ONCY

ONCY Price/Volume Stats

Current price $1.12 52-week high $3.21
Prev. close $1.08 52-week low $1.02
Day low $1.08 Volume 70,400
Day high $1.15 Avg. volume 273,049
50-day MA $1.38 Dividend yield N/A
200-day MA $1.74 Market Cap 64.55M

Oncolytics Biotech Inc. (ONCY) Company Bio


Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.


ONCY Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCY Latest Social Stream


Loading social stream, please wait...

View Full ONCY Social Stream

Latest ONCY News From Around the Web

Below are the latest news stories about Oncolytics Biotech Inc that investors may wish to consider to help them evaluate ONCY as an investment opportunity.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.

Yahoo | February 22, 2022

Oncolytics reports positive safety data in phase 1/2 pancreatic cancer group

Oncolytics Biotech (NASDAQ:ONCY) said no safety concerns were seen in the three-patient pancreatic cancer group of a phase 1/2 GOBLET study evaluating pelareorep in combination with Roche's (OTCQX:RHHBY) atezolizumab. Data Safety Monitoring Board recommended the study proceed as planned. The trial, which is being managed by Germany-based academic cooperative medical oncology group...

Seeking Alpha | February 2, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and recommended the study proceed as planned. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing.

Yahoo | February 2, 2022

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is t

Yahoo | January 27, 2022

Oncolytics rises 7% amid enrollment update on phase 1/2 gastrointestinal cancer study

Oncolytics Biotech <> provided enrollment update on a phase 1/2 GOBLET study of pelareorep in combination with Roche''s <> atezolizumab in patients with metastatic

Seeking Alpha | January 20, 2022

Read More 'ONCY' Stories Here

ONCY Price Returns

1-mo -13.18%
3-mo -33.33%
6-mo -34.88%
1-year -63.28%
3-year -39.13%
5-year -74.37%
YTD -19.42%
2021 -41.60%
2020 -50.00%
2019 162.98%
2018 -66.46%
2017 173.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4476 seconds.